219 related articles for article (PubMed ID: 23333599)
1. Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice.
Moreno JL; Holloway T; Rayannavar V; Sealfon SC; González-Maeso J
Neurosci Lett; 2013 Mar; 536():69-73. PubMed ID: 23333599
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
Moreno JL; Holloway T; Albizu L; Sealfon SC; González-Maeso J
Neurosci Lett; 2011 Apr; 493(3):76-9. PubMed ID: 21276828
[TBL] [Abstract][Full Text] [Related]
3. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies.
Lee MY; Chiang CC; Chiu HY; Chan MH; Chen HH
Neuropharmacology; 2014 Jun; 81():215-23. PubMed ID: 24534112
[TBL] [Abstract][Full Text] [Related]
5. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.
Fukumoto K; Iijima M; Chaki S
Psychopharmacology (Berl); 2014 Jun; 231(11):2291-8. PubMed ID: 24402133
[TBL] [Abstract][Full Text] [Related]
6. Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Moreno JL; Holloway T; Umali A; Rayannavar V; Sealfon SC; González-Maeso J
Psychopharmacology (Berl); 2013 Jan; 225(1):217-26. PubMed ID: 22842765
[TBL] [Abstract][Full Text] [Related]
7. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
[TBL] [Abstract][Full Text] [Related]
8. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Benneyworth MA; Xiang Z; Smith RL; Garcia EE; Conn PJ; Sanders-Bush E
Mol Pharmacol; 2007 Aug; 72(2):477-84. PubMed ID: 17526600
[TBL] [Abstract][Full Text] [Related]
9. Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.
Moreno JL; Kurita M; Holloway T; López J; Cadagan R; Martínez-Sobrido L; García-Sastre A; González-Maeso J
J Neurosci; 2011 Feb; 31(5):1863-72. PubMed ID: 21289196
[TBL] [Abstract][Full Text] [Related]
10. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors.
Gresch PJ; Strickland LV; Sanders-Bush E
Neuroscience; 2002; 114(3):707-13. PubMed ID: 12220572
[TBL] [Abstract][Full Text] [Related]
11. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
[TBL] [Abstract][Full Text] [Related]
12. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.
Gewirtz JC; Marek GJ
Neuropsychopharmacology; 2000 Nov; 23(5):569-76. PubMed ID: 11027922
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
Schindler EA; Dave KD; Smolock EM; Aloyo VJ; Harvey JA
Pharmacol Biochem Behav; 2012 Mar; 101(1):69-76. PubMed ID: 22197710
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.
Winter JC; Eckler JR; Rabin RA
Psychopharmacology (Berl); 2004 Mar; 172(2):233-40. PubMed ID: 14598016
[TBL] [Abstract][Full Text] [Related]
16. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
17. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
18. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
Linden AM; Bergeron M; Schoepp DD
Neuropharmacology; 2005; 49 Suppl 1():120-34. PubMed ID: 16023151
[TBL] [Abstract][Full Text] [Related]
19. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495.
Linden AM; Johnson BG; Trokovic N; Korpi ER; Schoepp DD
Neuropharmacology; 2009 Aug; 57(2):172-82. PubMed ID: 19477188
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
Buchborn T; Schröder H; Dieterich DC; Grecksch G; Höllt V
Behav Brain Res; 2015 Mar; 281():62-8. PubMed ID: 25513973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
